BioSpace News Archive

Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.

Novel Small Molecule and Antibody Conjugate Approaches Expected to Enable Broad Adoption of Boron Neutron Capture Therapy

Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, has obtained the occupancy permits for its newly built R&D Center for Innovative Drugs, meaning it has completed the construction of the facility.

LabMinds, Inc., an award-winning robotics company in life sciences, today announced it has closed a fully subscribed funding round from a mix of private and strategic investors.

Food Allergy Research & Education continues innovation through accelerated therapy, diagnostics and prevention strategies

PTU Elite: Soft Skills Program Sharpens Techs’ Skills to Foster Harmonious, Well-Rounded Pharmacy Teams

Biosimulation is an important part of systems biology and helps in the discovery and development of new drugs, in the area of drug metabolism and in the modeling of biomedical systems that are complex.

In 2016, the global market was valued at over US$ 49,994 Million characterizing the overwhelming popularity of antibody/antibody drugs amongst both practitioners and patients observed in recent years.

Sientra, Inc., a medical aesthetics company, announced that members of management will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced the European Patent Office granted the Company’s patent for a method of treating Alzheimer’s disease in humans by administering its lead compound, ANVS401.